Overview
AHIP and our members strongly support the use of medications for opioid use disorder (MOUD) as a valuable tool in helping patients manage opioid use disorder (OUD) and the ability of telemedicine to bring this treatment to patients who might not otherwise be able to access it. The Substance Abuse and Mental Health Services Administration (SAMHSA) has indicated there are no significant differences between telemedicine and in-person buprenorphine for continued substance use treatment, retention in treatment, or engagement in services.